Kailera Therapeutics (KLRA) Stock Price & Analysis
Score
AI Analysis
SnapshotKailera Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 72/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~217% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Kailera Therapeutics, Inc. (KLRA) last printed $13.27. Equity value is $1.72B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2025 |
|---|
| $0.00 |
About
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.